Amicus Therapeutics (FOLD) Spikes 20% Following Positive Phase Three Data

Shares of Amicus Therapeutics (FOLD) shot up more than 20% and printed the tape at a 52-week high of $5.47 on Wednesday after the company released positive data on its pill, migalastat, for Fabry disease – a rare genetic disorder in which fat builds up in the body – saying its Fabry disease treatment drug […] View the full post at: Amicus Therapeutics (FOLD) Spikes 20% Following Positive Phase Three Data Related posts: Economic Data: CPI Higher than Expected Economic Data for the Week of Sept. 8 – 11